Fisetin
Based on 35 publication(s) in Google Scholar
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.90%
- No. CAS: 528-48-3
- Fòrmula: C15H10O6
- Peso molecular:286.24
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-18085
QuercetinFlavonoid Antioxidant -
HY-10181
DasatinibSrc/Bcr-Abl Inhibitor -
HY-N0005
Curcuminp300 Histone Acetylatransferase Inhibitor -
HY-16561
ResveratrolPolyphenolic Phytoalexin -
HY-10087
NavitoclaxBcl-2 Inhibitor -
HY-10219
RapamycinmTOR Inhibitor -
HY-14590
KaempferolEstrogen Receptor α Inhibitor -
HY-N0196
BaicaleinXanthine Oxidase Inhibitor -
HY-N0162
LuteolinNrf2 Inhibitor -
HY-13653
(-)-Epigallocatechin GallateAnticancer Agent -
HY-B0627
MetforminAntihyperglycemic Agent -
HY-N0182R
Fisetin (Standard)
Publications Citing Use of MedChemExpress (MCE) Fisetin
More- Nat Aging. 2024 Apr;4(4):527-545. [Abstract]
- Cell Stem Cell. 2025 Dec 4;32(12):1869-1885.e8. [Abstract]
- Autophagy. 2026 Mar;22(3):445-467. [Abstract]
- Cell Rep Med. 2026 Jan 20;7(1):102532. [Abstract]
- Cell Death Dis. 2026 Apr 23;17(1):539. [Abstract]
- Acta Pharmacol Sin. 2023 Oct;44(10):2065-2074. [Abstract]
- Aging Cell. 2026 Jan 20;25(2):e70352.
- Mol Cancer Ther. 2025 Jul 2. [Abstract]
- JCI Insight. 2025 Jan 23;10(2):e180248. [Abstract]
- J Ethnopharmacol. 2024 Oct 28:333:118421. [Abstract]
- Biochem Pharmacol. 2025 Jul:237:116919. [Abstract]
- Cells. 2022 Jun 21;11(13):1992. [Abstract]
- Eur J Pharmacol. 2024 Feb 5:964:176298. [Abstract]
- Int J Mol Sci. 2026 Jun 22;27(12):5622. [Abstract]
- Biomolecules. 2025 Jun 16;15(6):873. [Abstract]
- Int J Mol Sci. 2025 May 22;26(11):4978. [Abstract]
- Biol Direct. 2025 Apr 2;20(1):43. [Abstract]
- J Nutr Biochem. 2023 Dec:122:109452. [Abstract]
- Molecules. 2023 Jul 20;28(14):5533. [Abstract]
- Food Sci Nutr. 2025 Sep 3;13(9):e70892. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jan;1871(1):167515. [Abstract]
- iScience. 2026 Mar 30;29(4):115521. [Abstract]
- Eur J Nutr. 2025 Mar 19;64(3):128. [Abstract]
- Fish Shellfish Immunol. 2025 Nov:166:110633. [Abstract]
- Microbiol Spectr. 2025 Aug 21:e0152725. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb;398(2):1665-1679. [Abstract]
- Hepatobiliary Pancreat Dis Int. 2021 Aug;20(4):352-360. [Abstract]
- PeerJ. 2025 Mar 28:13:e19198. [Abstract]
- Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303. [Abstract]
- bioRxiv. 2026 Jun 30.
- bioRxiv. 2024 Jul 30:2024.07.29.605645. [Abstract]
- Research Square Preprint. 2023 Nov 20.
- Journal of Harran University Medical Faculty. 2023 Sep 6.
- Aging (Albany NY). 2021 Nov 25;13(22):24753-24767. [Abstract]
- J Mol Liq. 23 November 2021, 118164.
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
Cell Imaging/Staining
-
WB
-
IF
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
IC50 & Target
Sirtuin, PPAR, TNF-alpha[1][2]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BV-2 | IC50 |
73.02 μM
Compound: 13
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
|
[PMID: 28911817] |
| BV-2 | IC50 |
13.5 μM
Compound: Fisetin
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS addition and measured after 24 hrs by Griess assay
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS addition and measured after 24 hrs by Griess assay
|
[PMID: 28923363] |
| BV-2 | IC50 |
13.5 μM
Compound: 92
|
Anti-inflammatory activity against mouse BV-2 cells assessed as LPS-induced inhibition of NO production
Anti-inflammatory activity against mouse BV-2 cells assessed as LPS-induced inhibition of NO production
|
[PMID: 37683361] |
| CWR22R | IC50 |
25.9 μM
Compound: 22
|
Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
|
[PMID: 22789812] |
| DU-145 | IC50 |
>50 μM
Compound: 2
|
Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay
Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay
|
[PMID: 28760528] |
| DU-145 | IC50 |
>50 μM
Compound: Fisetin
|
Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay
Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay
|
[PMID: 30165345] |
| H9 | EC50 |
122 μM
Compound: 14
|
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
|
[PMID: 8158164] |
| H9 | IC50 |
157 μM
Compound: 14
|
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
|
[PMID: 8158164] |
| HepG2 | IC50 |
>400 μM
Compound: 34
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 21726077] |
| HT-22 | EC50 |
2.8 μM
Compound: fisetin
|
Neuroprotective effect against iodoacetic acid-induced ischemia in mouse HT22 cells treated simultaneously with iodoacetic acid for 2 hrs followed by incubation in fresh medium containing drug alone for 20 hrs measured after 4 hrs by MTT assay
Neuroprotective effect against iodoacetic acid-induced ischemia in mouse HT22 cells treated simultaneously with iodoacetic acid for 2 hrs followed by incubation in fresh medium containing drug alone for 20 hrs measured after 4 hrs by MTT assay
|
[PMID: 19537799] |
| HT-22 | EC50 |
3 μM
Compound: Fisetin
|
Neuroprotective activity in mouse HT22 cells assessed as reduction in IAA-induced ischemia after 24 hrs by MTT assay
Neuroprotective activity in mouse HT22 cells assessed as reduction in IAA-induced ischemia after 24 hrs by MTT assay
|
[PMID: 22192055] |
| Huh-7 | CC50 |
>50 μM
Compound: 39
|
Cytotoxicity against human Huh7.5.1 cells by MTT assay
Cytotoxicity against human Huh7.5.1 cells by MTT assay
|
[PMID: 22445328] |
| KB | ED50 |
>100 μg/mL
Compound: NSC-407010
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 469554] |
| L6 | IC50 |
>30 μg/mL
Compound: 20
|
Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method
Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method
|
10.1039/C5MD00481K |
| L6 | IC50 |
38.5 μg/mL
Compound: 20
|
Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis
Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis
|
10.1039/C5MD00481K |
| LNCaP | IC50 |
34.1 μM
Compound: 2
|
Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay
Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay
|
[PMID: 28760528] |
| LNCaP | IC50 |
34.1 μM
Compound: Fisetin
|
Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay
Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay
|
[PMID: 30165345] |
| MCF-10A | IC50 |
2.44 μM
Compound: Fisetin
|
Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay
Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay
|
[PMID: 30165345] |
| Monocyte | IC50 |
3.7 μM
Compound: fisetin
|
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
|
[PMID: 8882428] |
| Monocyte | IC50 |
3.7 x 10-6 M
Compound: fisetin
|
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
|
[PMID: 8882428] |
| PC-3 | IC50 |
>50 μM
Compound: 2
|
Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay
Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay
|
[PMID: 28760528] |
| PC-3 | IC50 |
>50 μM
Compound: Fisetin
|
Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay
Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay
|
[PMID: 30165345] |
| PWR-1E | IC50 |
5.39 μM
Compound: Fisetin
|
Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay
Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay
|
[PMID: 30165345] |
| RD | EC50 |
84.48 μM
Compound: Fisetin
|
Antiviral activity against EV71 infected in human RD cells assessed as reduction in viral plaque formation after 1 hr by crystal violet staining method
Antiviral activity against EV71 infected in human RD cells assessed as reduction in viral plaque formation after 1 hr by crystal violet staining method
|
[PMID: 27776325] |
| THP-1 | IC50 |
30 μM
Compound: Fisetin
|
Cytotoxicity against human THP1 cells after 24 hrs by MTS assay
Cytotoxicity against human THP1 cells after 24 hrs by MTS assay
|
[PMID: 19879672] |
| THP-1 | IC50 |
30 μM/L
Compound: Fisetin
|
Cytotoxicity against human THP1 cells after 24 hrs by MTS assay
Cytotoxicity against human THP1 cells after 24 hrs by MTS assay
|
[PMID: 19879672] |
| Vero | IC50 |
55 μg/mL
Compound: fisetin
|
Antiviral activity against dengue virus 2 infected in african green monkey Vero cells assessed as reduction in viral replication dosed after adsorption with 200 FFU of virus for 1 hour by foci forming unit reduction assay
Antiviral activity against dengue virus 2 infected in african green monkey Vero cells assessed as reduction in viral replication dosed after adsorption with 200 FFU of virus for 1 hour by foci forming unit reduction assay
|
[PMID: 25564380] |
In Vitro
Fisetin inhibits lipid accumulation and suppresses the expression of PPARγ in 3T3-L1 cells. Fisetin suppresses early stages of preadipocyte differentiation, and induces expression of Sirt1. Fisetin facilitates Sirt1-mediated deacetylation of PPARγ and FoxO1, and enhances the association of Sirt1 with the PPARγ promoter, leading to suppression of PPARγ transcriptional activity, thereby repressing adipogenesis[1]. Fisetin binds to tubulin and stabilizes microtubules with binding characteristics far superior than paclitaxel. Fisetin treatment of human prostate cancer cells results in robust up-regulation of microtubule associated proteins (MAP)-2 and -4. Fisetin significantly inhibits PCa cell proliferation, migration, and invasion. Nudc, a protein associated with microtubule motor dynein/dynactin complex that regulates microtubule dynamics, is inhibited with Fisetin treatment[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 528-48-3
-
Appearance Solid
-
Peso molecular 286.24
-
Fòrmula C15H10O6
-
Color Light yellow to yellow
-
SMILES
O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC=C13
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (35)
-
Journal Impact Factor
-
Most Recent
-
Nat Aging
Spatiotemporal transcriptomic changes of human ovarian aging and the regulatory role of FOXP1. [Abstract]2024 Apr;4(4):527-545. PMID: 38594460
Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]
Fisetin (10 μM, 24 h), Quercetin (10 μM, 24 h) delayed FOXP1 gene silencing-induced cellular senescence in COV434 cells.
Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]
Fisetin (10 μM, 24 h), Quercetin (10 μM, 24 h) inhibited the FOXP1 silencing-induced increase in CDKN1A expression in COV434 cells.
Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]
Fisetin (10 μM, 24 h) and Quercetin (10 μM, 24 h) reversed the decrease in COV434 cell proliferation induced by FOXP1 knockdown.
Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]
Quercetin (10 μM, 24 h) but not Fisetin (10 μM, 24 h) delayed FOXP1 gene silencing in COV434 cells.
Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]
Quercetin (10 μM, 24 h) but not Fisetin (10 μM, 24 h) decreased γH2AX levels in COV434 cells.
-
Cell Stem Cell
Senolytic-sensitive p16Ink4a+ fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. [Abstract]2025 Dec 4;32(12):1869-1885.e8. PMID: 41187746 -
Autophagy
Restricting intracellular Salmonella proliferation by coordinating p-TBK1 mediated mitophagy and xenophagy. [Abstract]2026 Mar;22(3):445-467. PMID: 40660474 -
Cell Rep Med
Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. [Abstract]2026 Jan 20;7(1):102532. PMID: 41483805 -
Cell Death Dis
Subclonal β-catenin/YAP signaling heterogeneity accelerates ovarian cancer metastasis through a senescence-associated secretory phenotype. [Abstract]2026 Apr 23;17(1):539. PMID: 42026023 -
Acta Pharmacol Sin
Fisetin treatment alleviates kidney injury in mice with diabetes-exacerbated atherosclerosis through inhibiting CD36/fibrosis pathway. [Abstract]2023 Oct;44(10):2065-2074. PMID: 37225845 -
-
Mol Cancer Ther
Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4/6 inhibitors in prostate cancer. [Abstract]2025 Jul 2. PMID: 40601842 -
JCI Insight
Neutrophil extracellular traps potentiate effector T cells via endothelial senescence in uveitis. [Abstract]2025 Jan 23;10(2):e180248. PMID: 39846254 -
J Ethnopharmacol
Study on the anti-skin aging effect and mechanism of Sijunzi Tang based on network pharmacology and experimental validation. [Abstract]2024 Oct 28:333:118421. PMID: 38880400 -
Biochem Pharmacol
NUF2 activated by YY1 promotes prostate cancer malignancy via p38/MAPK signaling axis and serves as a therapeutic target. [Abstract]2025 Jul:237:116919. PMID: 40187571 -
Cells
EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263. [Abstract]2022 Jun 21;11(13):1992. PMID: 35805077 -
Eur J Pharmacol
Fisetin suppresses ferroptosis through Nrf2 and attenuates intervertebral disc degeneration in rats. [Abstract]2024 Feb 5:964:176298. PMID: 38145645 -
Int J Mol Sci
Synergistic Induction of Caspase-8-Mediated Leukaemic Cell Death by Fisetin and Pinocembrin. [Abstract]2026 Jun 22;27(12):5622. PMID: 42353336 -
Biomolecules
Targeting Cellular Senescence to Enhance Human Endometrial Stromal Cell Decidualization and Inhibit Their Migration. [Abstract]2025 Jun 16;15(6):873. PMID: 40563513 -
Int J Mol Sci
Fisetin Attenuates Zinc Overload-Induced Hepatotoxicity in Mice via Autophagy-Dependent Nrf2 Activation. [Abstract]2025 May 22;26(11):4978. PMID: 40507790 -
Biol Direct
GAMT facilitates tumor progression via inhibiting p53 in clear cell renal cell carcinoma. [Abstract]2025 Apr 2;20(1):43. PMID: 40176130 -
J Nutr Biochem
F6P/G6P-mediated ChREBP activation promotes the insulin resistance-driven hepatic lipid deposition in zebrafish. [Abstract]2023 Dec:122:109452. PMID: 37748621 -
Molecules
Fisetin Delays Postovulatory Oocyte Aging by Regulating Oxidative Stress and Mitochondrial Function through Sirt1 Pathway. [Abstract]2023 Jul 20;28(14):5533. PMID: 37513404 -
Food Sci Nutr
Flavonoids in Rosa roxburghii Tratt Fermentation Broth Ameliorate Obesity via DNMT3a/SIRT1-Mediated Epigenetic Modulation. [Abstract]2025 Sep 3;13(9):e70892. PMID: 40909259 -
Biochim Biophys Acta Mol Basis Dis
MISP-mediated enhancement of pancreatic cancer growth through the Wnt/β-catenin signaling pathway is suppressed by Fisetin. [Abstract]2025 Jan;1871(1):167515. PMID: 39278512 -
iScience
pH-responsive Folate-PEG modified ZIF-8 Nanoparticles deliver fisetin to Aquaporin-3 for cervical cancer therapy. [Abstract]2026 Mar 30;29(4):115521. PMID: 42006369 -
Eur J Nutr
Fisetin alleviates Salmonella typhimurium-induced colitis through the TLR2/TLR4-NF-κB pathway, regulating microbiota, and repressing intracellular bacterial proliferation by focal adhesion kinase. [Abstract]2025 Mar 19;64(3):128. PMID: 40106033 -
Fish Shellfish Immunol
Emodin enhances host antiviral immunity against Micropterus salmoides rhabdovirus by activating RLR signaling in largemouth bass. [Abstract]2025 Nov:166:110633. PMID: 40769268 -
Microbiol Spectr
2025 Aug 21:e0152725. PMID: 40838703 -
Naunyn Schmiedebergs Arch Pharmacol
Therapeutic use of fisetin and pirfenidone combination in bleomycin-induced pulmonary fibrosis in adult male albino rats. [Abstract]2025 Feb;398(2):1665-1679. PMID: 39162796 -
Hepatobiliary Pancreat Dis Int
Fisetin mitigates hepatic ischemia-reperfusion injury by regulating GSK3β/AMPK/NLRP3 inflammasome pathway. [Abstract]2021 Aug;20(4):352-360. PMID: 34024736 -
PeerJ
Fisetin may protect early porcine embryos from oxidative stress by down-regulating GRP78 levels. [Abstract]2025 Mar 28:13:e19198. PMID: 40166042 -
Biochem Biophys Res Commun
Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]2018 Sep 3;503(1):297-303. PMID: 29890135 -
-
bioRxiv
2024 Jul 30:2024.07.29.605645. PMID: 39131266 -
-
-
Aging (Albany NY)
Fisetin inhibits the proliferation, migration and invasion of pancreatic cancer by targeting PI3K/AKT/mTOR signaling. [Abstract]2021 Nov 25;13(22):24753-24767. PMID: 34821587 -
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (349.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Cell Assay[1]
3T3-L1 cells are transfected with reporter vector, and expression plasmids using TransIT-LT1. After 24 h, media is replaced with viral supernatant. After 15-18 h of infection, media is replaced with DMI, 0.1 μM troglitazone and Fisetin (50 μM). Cells are lysed using cell culture lysis buffer two days after addition of differentiation stimulus. Luciferase activity is determined using an analytical luminescence luminometer[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration[3]
Mice: The mice are divided into six groups of eight animals each. The mice in the first group are topically treated with 0.2 mL acetone and used as vehicle control. The mice in the second and third groups receive topical treatment of Fisetin 250 nmol/0.2 mL acetone/mouse and 500 nmol/0.2 mL acetone/mouse respectively on their dorsal skin and serves as agent controls. The mice in the fourth, fifth and sixth groups are exposed to UVB. The mice in the fourth group receive a topical application of 0.2 mL acetone after 15 min of UVB exposure designated as vehicle control. The mice in the fifth and sixth groups are treated with topical application of Fisetin 250 nmol/0.2 mL acetone/mouse and 500 nmol/0.2 mL acetone/mouse respectively on to their dorsal skin after 15 min of UVB exposure[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Kim SC, et al. Fisetin induces Sirt1 expression while inhibiting early adipogenesis in 3T3-L1 cells. Biochem Biophys Res Commun. 2015 Nov 27;467(4):638-44. [Content Brief]
[2]. Mukhtar E, et al. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells. Cancer Lett. 2015 Oct 28;367(2):173-83. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4936 mL | 17.4679 mL | 34.9357 mL | 87.3393 mL |
| 5 mM | 0.6987 mL | 3.4936 mL | 6.9871 mL | 17.4679 mL | |
| 10 mM | 0.3494 mL | 1.7468 mL | 3.4936 mL | 8.7339 mL | |
| 15 mM | 0.2329 mL | 1.1645 mL | 2.3290 mL | 5.8226 mL | |
| 20 mM | 0.1747 mL | 0.8734 mL | 1.7468 mL | 4.3670 mL | |
| 25 mM | 0.1397 mL | 0.6987 mL | 1.3974 mL | 3.4936 mL | |
| 30 mM | 0.1165 mL | 0.5823 mL | 1.1645 mL | 2.9113 mL | |
| 40 mM | 0.0873 mL | 0.4367 mL | 0.8734 mL | 2.1835 mL | |
| 50 mM | 0.0699 mL | 0.3494 mL | 0.6987 mL | 1.7468 mL | |
| 60 mM | 0.0582 mL | 0.2911 mL | 0.5823 mL | 1.4557 mL | |
| 80 mM | 0.0437 mL | 0.2183 mL | 0.4367 mL | 1.0917 mL | |
| 100 mM | 0.0349 mL | 0.1747 mL | 0.3494 mL | 0.8734 mL |
Fisetin Related Classifications
HY-N0182 Related Classifications
Powered by Bioz